Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer

This study is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy before chemoradiation improves outcomes for patients with locally advanced cervical cancer. The approach is called induction therapy — treatment given before the main course of treatment to try to shrink the cancer first. **You may be eligible if...** - You have been newly diagnosed with locally advanced cervical cancer (FIGO stage IIIB–IVA) that has not yet been treated - Pathology has confirmed the cancer type - You are in reasonably good health (ECOG 0-1) with a life expectancy of at least 6 months - Your blood, kidney, and liver function are adequate - You are female and willing to use effective contraception during the study **You may NOT be eligible if...** - You have another current cancer - You are pregnant or breastfeeding - You have active bleeding - You have serious autoimmune disease or other severe medical conditions Talk to your doctor to see if this trial is right for you.